

CEO Dr. Daniel Teper to Co-Host and Speak on A Panel at Cancer Advance Boston at Harvard Medical School on April 5, 2016 at 9:50 AM

Date : March 18, 2016

Checkpoint Inhibitors: What's New? [9:50-10:30 AM]

Harry Gruber, Tocagen; **Christian Rohlff**, Oxford BioTherapeutics; **Daniel Teper**, Immune Pharmaceuticals; **Kevin Webster**, eFFECTOR Therapeutics

Moderator: **Joanna Horobin**, Idera Pharma

